NCT03582982

Brief Summary

Among Veterans, the prevalence of chronic kidney disease (CKD) is reported to be as high as 47.3% and a third higher than the general population. Muscle wasting and dysfunction have been identified as primary consequences of CKD. Disease-induced reductions in lean tissue adversely affect muscle fatigability. Consequently, muscle fatigability may serve as a potential limiting factor that contributes to activity limitations. However, there is a lack of evidence informing our understanding of muscle fatigability in patients with CKD. Dialysis treatment is a major factor contributing to the high financial costs of CKD care. Thus, in addition to potential health and quality of life benefits, treatments capable of maintaining kidney function or delaying the onset of dialysis treatment would provide substantial socio-economic benefit. Both lean body mass and muscle fatigability may be improved through strength training. Eccentric-overload (i.e. muscle lengthening) progressive resistance exercise (PRE) has been shown to be safe and effective for a variety of chronic conditions. Eccentric PRE using portable flywheel technology may provide a clinically viable treatment option to combat muscle impairments in CKD given the cost effectiveness and minimal space requirements for this mode of exercise. The purpose of this study is to assess feasibility of the eccentric-overload PRE regimen for Veterans with CKD stage 3 \& 4 predialysis using a prospective single-arm pre-test post-test intervention design. The primary aim of the project is to determine the effects of eccentric-overload PRE on muscle fatigability in Veterans with CKD Stages 3 \& 4 predialysis. Feasibility of the regimen will be determined by the time needed to complete the 4-exercise regimen and the perceived exertion levels reported by the study participants.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 16, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 15, 2018

Completed
26 days until next milestone

First Posted

Study publicly available on registry

July 11, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

November 9, 2018

Status Verified

November 1, 2018

Enrollment Period

9 months

First QC Date

June 15, 2018

Last Update Submit

November 8, 2018

Conditions

Keywords

resistance exercisemuscle fatiguephysical function

Outcome Measures

Primary Outcomes (7)

  • Change in Knee extensor isokinetic muscle fatigability index at 12 weeks

    Knee extensor muscle fatigability will be assessed using a protocol consisting of 30 repetitions or to failure, whichever comes first, at their maximum strength

    Baseline, Week 12

  • Change in Muscle blood flow at 12 weeks

    Blood flow will be assessed using Doppler ultrasound

    Baseline, Week 12

  • Change in Isokinetic and isometric peak knee extension force at 12 weeks

    Unilateral peak knee extension/flexion isokinetic force (at 180º/s and 60º/s) will be obtained across five continuous repetitions using a load cell

    Baseline, Week 6, Week 12

  • Change in Short Physical Performance Battery at 12 weeks

    This composite score is made up of measures of balance, gait speed (15 ft), and timed chair stands (x5).

    Baseline, Week 12

  • Change in Timed Up-and-Go at 12 weeks

    This test will begin the test with the subject fully sitting in a chair with arm rests, with the upright mobility portion of the test focused on an easily visible marked target 3 meters away from the chair

    Baseline, Week 12

  • Change in Lean Body Mass, as estimated by diagnostic ultrasound at 12 weeks

    Sonographic estimates of LBM (aggregate muscle thickness, cm) will serve as a proxy measure for muscle tissue composition in this study

    Baseline, Week 6, Week 12

  • Change in myosteatosis, as estimated by diagnostic ultrasound at 12 weeks

    Sonographic estimates of myosteatosis (grayscale, or GSL, values, 0-255) will serve as a proxy measure for muscle tissue composition in this study

    Baseline, Week 6, Week 12

Secondary Outcomes (8)

  • Change in Grip strength at 12 weeks

    Baseline, Week 12

  • Change in Activities-Specific Balance Confidence (ABC) Scale at 12 weeks

    Baseline, Week 12

  • Change in Short Form Health Survey (SF-36) Scale at 12 weeks

    Baseline, Week 12

  • Change in Falls Efficacy Scale (FES) at 12 weeks

    Baseline, Week 12

  • Change in weight at 12 weeks

    Baseline, Week 6, Week 12

  • +3 more secondary outcomes

Study Arms (1)

Eccentric overload exercise

EXPERIMENTAL
Behavioral: Eccentric overload exercise

Interventions

12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.

Eccentric overload exercise

Eligibility Criteria

Age18 Years - 84 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ambulatory patients (with or without a gait aid)
  • CKD stage 3 or 4
  • patients receiving care at the DC VAMC Renal Service
  • the ability to speak and read English
  • orientation to person, place, and time

You may not qualify if:

  • unable to speak English
  • acute renal failure
  • pregnant
  • unable to follow study instructions
  • any uncontrolled cardiovascular or musculoskeletal problems that would make participation in this study unsafe

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington DC VA Medical Center

Washington D.C., District of Columbia, 20422, United States

RECRUITING

Study Officials

  • Michael O Harris-Love, DSc

    Washington DC VA Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jared M Gollie, PhD

CONTACT

Brian M Hoover, MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 15, 2018

First Posted

July 11, 2018

Study Start

May 16, 2018

Primary Completion

February 1, 2019

Study Completion

February 1, 2020

Last Updated

November 9, 2018

Record last verified: 2018-11

Data Sharing

IPD Sharing
Will not share

Locations